Protocol
11-064
Full Title
A Phase II Evaluation of Pazopanib (NSC # 737754, IND #75648) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus (GOG-0230D)
Purpose
Pazopanib is an oral medication (taken by mouth) which fights cancers by interfering with the development and growth of the blood vessels tumors need to grow and spread. It is approved for treating an aggressive form of kidney cancer called renal cell carcinoma.
In this Gynecologic Oncology Group study, researchers want to see if pazopanib is effective against a type of uterine cancer called carcinosarcoma that has recurred or persisted despite treatment.
Investigator
Hensley, Martee, MD
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have uterine carcinosarcoma (mixed mesodermal tumor) that has recurred or persisted despite prior therapy that included at least one regimen of chemotherapy.
- At least 1 week must have passed since completion of any hormonal therapy, 3 weeks since prior chemotherapy, and 4 weeks since prior radiation therapy or major surgery and entry into the study. Patients must have recovered from any side effects.
- Patients must be age 18 or older.
For more information and to see if you are eligible for this study, please contact Dr. Martee L. Hensley at 212-639-6902.
Disease(s)
Sarcoma
Soft Tissue Sarcoma
Uterine Cancer
